Form 4: XBiotech Director Granted Stock Options

XBiotech Inc. director Thomas Kuendig was granted 79,115 nonstatutory stock options with an exercise price of $2.64, vesting in two tranches.

Summary

• Thomas Martin Kuendig, a Director of XBiotech Inc. (XBIT), was granted nonstatutory stock options on October 1, 2025.
• The grant consists of 79,115 derivative securities (stock options) to purchase an equal number of shares of the Company's Common Stock.
• The exercise price for these options is $2.64 per share, which was the closing sales price on the Nasdaq Stock Market on the grant date.
• The options will vest in two equal portions: the first 50% will vest four months from the grant date, and the remaining 50% will vest ten months from the grant date.
• The options have an expiration date of ten years from the grant date, specifically October 1, 2035.

Sentiment

Score: 7

Explanation: This filing reports a routine grant of stock options to a director, which is a positive event for aligning interests but not a significant operational or financial announcement that would drastically alter sentiment.

Positives

• The grant of stock options to a director aligns management's long-term interests with those of the shareholders, incentivizing performance and value creation.
• The exercise price is set at the closing market price on the grant date, indicating a standard compensation practice.

Future Outlook

The options are scheduled to vest in two equal portions at four months and ten months from the grant date, with an expiration date ten years from the grant date.

Management Comments

• Thomas Kuendig was granted nonstatutory stock options under the Company's 2025 Equity Incentive Plan on October 1, 2025.
• The options vest in two equal portions at four months and ten months from the grant date and expire ten years from the grant date.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and broader corporate sectors, serving as a form of long-term incentive compensation to align the interests of directors with those of shareholders.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across various industries, including biotechnology.
• The vesting schedule (two tranches over ten months) and a ten-year expiry are typical for such equity awards, designed to encourage long-term commitment and performance.
• The exercise price being equal to the closing market price on the grant date is also a standard approach for nonstatutory options, distinguishing them from discounted options.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: While this specific grant is for a director, the existence of an Equity Incentive Plan suggests a broader framework for equity compensation that could benefit other key personnel.

Next Steps

• The granted options will vest in two equal portions, four months and ten months from the grant date (October 1, 2025).

Key Dates

Keywords

XBiotech, XBIT, Stock Options, Director Compensation, Form 4, Insider Transaction, Equity Incentive Plan, Thomas Kuendig